Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: This interim analysis of a phase 1/2, open-label, single-arm study assessed the safety, efficacy, and pharmacokinetics of gilteritinib plus chemotherapy in adults with newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Methods: In sequential phase 1 and 2 studies, induction and consolidation therapy with gilteritinib 120 mg/day plus chemotherapy (induction: idarubicin/cytarabine once daily; consolidation: cytarabine twice daily) was followed by maintenance gilteritinib 120 mg/day monotherapy. Endpoints included maximum tolerated dose (MTD), recommended expansion dose (RED), and dose-limiting toxicity (phase 1), and complete remission (CR) rate following induction therapy (primary endpoint), overall survival (OS), safety, and pharmacokinetics (phase 2).
Results: In phase 1, MTD was not reached and RED was 120 mg/day. In phase 2, the CR rate was 50.0% after induction (90% confidence interval [CI] 40.4, 59.6); however, the lower confidence limit did not exceed the pre-defined 55% benchmark. Composite CR (CRc) rates were high following induction (86.6%, 95% CI [77.3, 93.1]), consolidation, and maintenance therapy (87.8%, 95% CI [78.7, 94.0], each). The probability of OS was 86.6% at 12 months. No new safety findings were reported.
Conclusion: In this interim analysis, gilteritinib 120 mg/day in combination with chemotherapy was well tolerated, with similar CRc rates to previous studies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11748473 | PMC |
| http://dx.doi.org/10.1007/s12185-024-03840-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inadequate Cancer Pain Control after Switching High-Dose Fentanyl to Hydromorphone Injection: A Case Series Highlighting Issues with Conventional Conversion Ratios.
Palliat Med Rep
September 2025
Department of Pharmacy, Yamagata Prefectural Central Hospital, Yamagata, Yamagata, Japan.
Opioid conversion, particularly from high-dose intravenous (IV) fentanyl (>120 mg/day oral morphine-equivalent daily dose per referenced Japanese guidelines) to IV hydromorphone, presents clinical challenges due to inconsistent conversion ratios and lack of robust evidence. Specific approaches used in Japan may require careful evaluation. This report details two advanced cancer patients experiencing inadequate pain control after switching from high-dose IV fentanyl to IV hydromorphone.
View Article and Find Full Text PDFPatient-reported efficacy of adjunctive brexpiprazole in major depressive disorder in a phase 4, open-label, interventional study.
Curr Med Res Opin
September 2025
Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA.
Objectives: In ENGAGE, patients with major depressive disorder (MDD) demonstrated improvements in patient-reported depression and life engagement while taking adjunctive brexpiprazole. This analysis aimed to further characterize patient perspectives on the effects of adjunctive brexpiprazole, using patient diary data from ENGAGE, and describe development of a 'word of the day' activity.
Methods: Prior to ENGAGE, word lists describing a 'good,' 'average,' and 'bad' day with depression were generated from semi-structured interviews with patients with MDD.
Satralizumab treatment in neuromyelitis optica spectrum disorder: effects on relapse, pain, and other medications used: a retrospective chart review.
Mult Scler Relat Disord
August 2025
Department of Neurology, Tokyo Women's Medical University, Japan.
Background: Glucocorticoids and immunosuppressants are used for neuromyelitis optica spectrum disorder (NMOSD) relapse suppression. Recently, biologics have demonstrated efficacy in relapse prevention. We aimed to evaluate the effects of satralizumab, an interleukin-6 receptor inhibitor, on relapse prevention, pain management, glucocorticoid tapering, and number of medications.
View Article and Find Full Text PDFBackground: The article presents the results of a prospective open-label comparative interventional study of the efficacy and safety of high-dose dual therapy (HDDT) for eradicating infection.
Aim: To evaluate the efficacy and safety of HDDT of the eradication regimen, as well as the possible increase in the efficacy of this regimen with the addition of rebamipide.
Materials And Methods: All patients with verified infection were randomized into three groups depending on the treatment regimen.
Levomilnacipran, but Not Duloxetine, Inhibits Serotonin and Norepinephrine Reuptake Throughout Its Therapeutic Range.
J Clin Psychiatry
August 2025
University of Ottawa Institute of Mental Health Research at The Royal, Ottawa, Canada.
The primary aim of this study was to establish that levomilnacipran potently inhibits norepinephrine (NE) reuptake in human participants starting at a minimally efficacious regimen in major depressive disorder (MDD) and to determine the dose needed to significantly inhibit serotonin (5-HT) reuptake. The secondary aim was to confirm that duloxetine is a selective 5-HT reuptake inhibitor at its minimally effective regimen in MDD and that it significantly inhibits NE reuptake only with dose escalation. Inhibition of the NE reuptake process was estimated by assessing the attenuation of the systolic blood pressure produced by intravenous injections of small doses of tyramine.
View Article and Find Full Text PDF